Comparative effectiveness of plasma prepared with amotosalen-UVA pathogen inactivation and conventional plasma for support of liver transplantation

Transfusion

Volumn 55, Issue 7, 2015, Pages 1710-1720

  Cinqualbre, Jacques ^a   Kientz, Daniel ^b   Remy, Emilie ^b   Huang, Norman ^c   Corash, Laurence ^c   Cazenave, Jean Pierre ^d  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c CERUS CORPORATION   (United States)

^d Armesa   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; FRESH FROZEN PLASMA; FUROCOUMARIN DERIVATIVE; PHOTOSENSITIZING AGENT;

ADULT; ARTICLE; BLOOD COMPONENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT COLD PERFUSION TIME; GRAFT PERFUSION; HEMATOCRIT; HEPATIC ARTERY THROMBOSIS; HUMAN; INFECTION; INFECTION CONTROL; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MODEL FOR END STAGE LIVER DISEASE SCORE; MORBIDITY; MORTALITY; PATIENT SAFETY; PLASMA TRANSFUSION; PLASMA VOLUME; PREOPERATIVE PERIOD; THROMBOCYTE TRANSFUSION; TRANSFUSION TRANSMITTED INFECTION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; BLOOD COMPONENT THERAPY; COMPARATIVE STUDY; DISINFECTION; MIDDLE AGED; PLASMA; RETROSPECTIVE STUDY; ULTRAVIOLET RADIATION;

ADULT; BLOOD COMPONENT TRANSFUSION; DISINFECTION; FEMALE; FUROCOUMARINS; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHOTOSENSITIZING AGENTS; PLASMA; RETROSPECTIVE STUDIES; ULTRAVIOLET RAYS;

EID: 84937022864     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13100     Document Type: Article

References (28)

1. Massicotte L, Denault AY, Beaulieu D, et al., Transfusion rate for 500 consecutive liver transplantations: experience of one liver transplantation center. Transplantation 2012; 93: 1276-81.
2. Busch MP, Murthy KK, Kleinman SH, et al., Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes. Blood 2012; 119: 6326-34.
3. Allain JP,. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004; 86: 83-91.
4. Kleinman S, Cameron C, Custer B, et al., Modeling the risk of an emerging pathogen entering the Canadian blood supply. Transfusion 2010; 50: 2592-606.
5. Stramer SL, Hollinger FB, Katz LM, et al., Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49: 1S-29S.
6. Petersen LR, Epstein JS,. Chikungunya virus: new risk to transfusion safety in the Americas. Transfusion 2014; 54: 1911-5.
7. Singh Y, Sawyer L, Pinkoski L, et al., Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006; 46: 1168-77.
8. Musso D, Richard V, Broult J, et al., Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 2014; 54: 2924-30.
9. Bartelmaos T, Chabanel A, Léger J, et al., Plasma transfusion in liver transplantation: a randomized, double-blind, multicenter clinical comparison of three virally secured plasmas. Transfusion 2013; 53: 1335-45.
10. Cazenave JP, Waller C, Kientz D, et al., An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010; 50: 1210-9.
11. Klein HG, Anderson D, Bernardi MJ, et al., Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007; 47: 2338-47.
12. Atance R, Pereira A, Ramírez B,. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001; 41: 1548-52.
13. Teutsch SM, Fielding JE,. Comparative effectiveness-looking under the lamppost. JAMA 2011; 305: 2225-6.
14. Mintz PD, Bass NM, Petz LD, et al., Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107: 3753-60.
15. Schlenke P, Hervig T, Isola H, et al., Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 2008; 48: 697-705.
16. Abdel-Wahab OI, Healy B, Dzik WH,. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006; 46: 1279-85.
17. Stanworth SJ, Grant-Casey J, Lowe D, et al., The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children. Transfusion 2011; 51: 62-70.
18. Williamson LM, Llewelyn CA, Fisher NC, et al., A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999; 39: 1227-34.
19. Youssef WI, Salazar F, Dasarathy S, et al., Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 2003; 98: 1391-4.
20. Tripodi A, Anstee QM, Sogaard KK, et al., Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011; 9: 1713-23.
21. Tripodi A, Chantarangkul V, Primignani M, et al., Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. Intern Emerg Med 2012; 7: 139-44.
22. Cacciarelli TV, Keeffe EB, Moore DH, et al., Effect of intraoperative blood transfusion on patient outcome in hepatic transplantation. Arch Surg 1999; 134: 25-9.
23. de Boer MT, Christensen MC, Asmussen M, et al., The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg 2008; 106: 32-44, table of contents.
24. Massicotte L, Sassine MP, Lenis S, et al., Survival rate changes with transfusion of blood products during liver transplantation. Can J Anaesth 2005; 52: 148-55.
25. Xia VW, Du B, Braunfeld M, et al., Preoperative characteristics and intraoperative transfusion and vasopressor requirements in patients with low vs. high MELD scores. Liver Transpl 2006; 12: 614-20.
26. Wagner AK, Soumerai SB, Zhang F, et al., Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27: 299-309.
27. Product circular for pooled plasma, solvent detergent treated. Saint-Egreve (France): V.I. Technologies, Inc.; 2002.
28. Tripodi A, Mannucci PM,. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-56.